Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Overview
Neurocrine Biosciences Inc is a neuroscience-focused, product-based biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments that address significant unmet medical needs. Combining deep expertise in neurology, endocrinology, and neuropsychiatry, the company has established itself in creating therapies for conditions ranging from tardive dyskinesia and Huntington's disease chorea to endocrine disorders like congenital adrenal hyperplasia and conditions related to reproductive health. Through robust research and strategic development, Neurocrine Biosciences leverages state-of-the-art scientific approaches and clinical insights to provide treatments that target complex pathologies with precision.
Core Competencies and Therapeutic Focus
Neurocrine Biosciences stands at the nexus of innovative drug discovery and clinical excellence. Its core therapeutic areas revolve around:
- Neurological Disorders: Developing treatments that target abnormal involuntary movements and other neurological conditions by modulating key neurotransmitter systems.
- Neuroendocrine and Endocrine Disorders: Researching and launching products addressing hormonal imbalances and disorders such as congenital adrenal hyperplasia and endometriosis, where traditional therapies have long been challenged.
- Neuropsychiatric Conditions: Investigating the interconnections between brain and body to develop therapies that alleviate symptoms associated with cognitive impairment, mood disorders, and related conditions.
Product Portfolio and Pipeline
With a diversified portfolio, Neurocrine Biosciences has successfully brought several therapeutics to market while continuously advancing a pipeline of innovative drug candidates. Its flagship products focus on alleviating severe movement disorders; for example, its products for tardive dyskinesia and chorea associated with Huntington's disease utilize mechanisms that adjust dopamine signaling via selective inhibition of vesicular monoamine transporters. Additionally, the company has pioneered new therapeutic approaches for conditions historically managed with high-dose steroids, offering promising alternatives that target the underlying neuroendocrine pathways. This balanced product and pipeline strategy exemplifies its commitment to addressing very specific niches within the broader pharmaceutical market.
Research, Development, and Scientific Rigor
Emphasizing advanced research methodologies, Neurocrine Biosciences consistently applies its unique scientific insights to unravel the complexities of brain and body interactions. The company’s research and development efforts are grounded in clinical evidence and rigorous scientific validation, ensuring that each therapy is backed by robust data from well-designed studies. This dedication to scientific rigor not only enhances the credibility of its products but also ensures adherence to the highest safety and efficacy standards, a cornerstone of its operational ethos.
Market Position and Competitive Edge
Operating in a highly specialized niche within the biopharmaceutical sector, Neurocrine Biosciences differentiates itself with a deep commitment to patient-centric innovation and complex disease understanding. The company’s extensive experience over several decades, combined with its targeted research, underscores its authority in neurotherapeutics. Rather than taking a broad-market approach, it focuses on disease areas with significant unmet needs, building a competitive edge through tailored therapeutic solutions and a strong commitment to clinical excellence.
Conclusion
In summary, Neurocrine Biosciences Inc is a prime example of a modern, scientifically driven biopharmaceutical company that employs its deep understanding of neuroscience and endocrinology to develop treatments for conditions that have long challenged conventional medical approaches. Its blend of clinical innovation, rigorous research, and targeted treatment strategies positions it as a trusted name in addressing some of the most complex neurologically and endocrinologically related diseases. For investors and medical professionals alike, the company represents an enduring commitment to relieving suffering through brave science and thoughtful, evidence-based solutions.
Neurocrine Biosciences (Nasdaq: NBIX) reported preliminary net product sales for INGREZZA of approximately $240 million in Q4 2020 and $993 million for the full year. The company noted a 32% growth in total INGREZZA prescriptions in 2020, reaching 175,700 versus 132,700 in 2019. Key 2021 milestones include Phase III data for valbenazine in Huntington's disease expected in Q4 2021 and the initiation of several clinical studies. CEO Kevin Gorman highlighted the commitment to improving treatment accessibility for tardive dyskinesia patients.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. Eastern Time. CEO Kevin Gorman will lead the presentation, which will be available via live webcast on the company's website. A replay will be accessible one hour post-event and archived for a month. Neurocrine focuses on developing treatments for neurological, endocrine, and psychiatric disorders, with FDA-approved therapies for conditions like tardive dyskinesia and Parkinson's disease. For more information, visit neurocrine.com.
Neurocrine Biosciences (Nasdaq: NBIX) announced upcoming presentations at two investor conferences. Matt Abernethy, CFO, and Eiry Roberts, CMO, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on November 23, 2020, at 10:00 a.m. ET. Additionally, CEO Kevin Gorman and CFO Abernethy will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 1:50 p.m. ET. Live webcasts will be available on their website, with replays accessible for one month.
Neurocrine Biosciences (Nasdaq: NBIX) has initiated a repurchase of approximately $83 million of its 2.25% Convertible Senior Notes due 2024. The aggregate repurchase price is estimated at $110 million based on the closing stock price of $86.91 on November 18, 2020. The transaction is expected to close on December 2, 2020. This strategic buyback aims to potentially enhance shareholder value, but may also impact the market price of the company's common stock.
Neurocrine Biosciences (NBIX) reported Q3 2020 revenues of $258.5 million, a 16.4% increase from $222.1 million in Q3 2019, driven by a 28% rise in INGREZZA sales to $254 million. However, the company faced a GAAP net loss of $57.6 million compared to a profit of $53.8 million in the previous year, largely due to increased R&D expenses. The guidance for combined GAAP R&D and SG&A expenses was raised to between $880 million and $900 million. Despite the challenges, the company expressed confidence in its growth prospects, particularly for INGREZZA and the newly launched ONGENTYS.
Neurocrine Biosciences (Nasdaq: NBIX) announced upcoming presentations at investor conferences. Kevin Gorman, CEO, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 11:20 a.m. ET. On November 17, 2020, at 9:40 a.m. ET, Gorman and CFO Matt Abernethy will present at the Jefferies Virtual London Healthcare Conference. Both presentations will be available via webcast on Neurocrine's website, with replays accessible for one month.
Neurocrine focuses on developing treatments for neurological and endocrine disorders.
Neurocrine Biosciences (Nasdaq: NBIX) will report its third-quarter financial results after market close on November 9, 2020. A conference call will follow at 1:30 p.m. PT, 4:30 p.m. ET, to discuss the results and provide updates. Participants can access the call at 877-830-2596 (US) or 785-424-1744 (International) with conference ID: NBIX. The event will be available for replay on the company's website for approximately one month. Neurocrine specializes in developing treatments for neurological and psychiatric disorders.
On September 28, 2020, Neurocrine Biosciences (Nasdaq: NBIX) announced new data on ONGENTYS® (opicapone) capsules, the first once-daily COMT inhibitor approved by the FDA for Parkinson's disease patients experiencing 'off' episodes. Phase III analyses reveal ONGENTYS significantly reduces overnight 'off' time and motor fluctuations compared to entacapone. This data will be presented at the American Neurological Association 2020 Virtual Meeting. ONGENTYS also shows promise in lowering daily levodopa requirements, enhancing 'on' time without troublesome dyskinesia.
Neurocrine Biosciences has announced the availability of ONGENTYS (opicapone) in 50 mg capsules, the first FDA-approved once-daily COMT inhibitor for Parkinson's disease. Approved on April 24, 2020, ONGENTYS is an add-on treatment for patients experiencing 'off' episodes while on levodopa/carbidopa. Approximately 1 million Americans suffer from Parkinson's, with about 50,000 new diagnoses each year. Clinical studies indicate ONGENTYS significantly reduces 'off' time and increases 'on' time without troublesome dyskinesia, reflecting a commitment to innovative therapies in movement disorders.
Neurocrine Biosciences (NBIX) announced significant results from post-hoc analyses of Phase III studies demonstrating that ONGENTYS (opicapone) capsules effectively reduce "off" time and increase "on" time in Parkinson's disease patients as an add-on to levodopa/carbidopa. ONGENTYS, approved by the FDA in April 2020, showed that 50 mg doses reduced "off" time by over an hour compared to placebo. Additionally, real-world data revealed increased hospitalization rates linked with prolonged motor fluctuations. The data will be showcased at the MDS Virtual Congress 2020.
FAQ
What is the current stock price of Neurocrine Biosciences (NBIX)?
What is the market cap of Neurocrine Biosciences (NBIX)?
What is the core focus of Neurocrine Biosciences Inc?
Which therapeutic areas does Neurocrine primarily target?
How does Neurocrine differentiate itself in the biopharmaceutical industry?
What role does clinical research play in Neurocrine's strategy?
Does Neurocrine have a diversified product portfolio?
How are Neurocrine's therapies developed?
Who are the typical beneficiaries of Neurocrine's treatments?
How does Neurocrine ensure the quality and reliability of its products?
